Compare Novartis AG (NVS) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs PubMatic Inc — how do they compare? Novartis AG trades at $143.12 (market cap $268.57B), while PubMatic Inc trades at $18.7 (market cap $850.88M). The key difference: Novartis AG is far larger — about 315.6× PubMatic Inc's market cap, and Novartis AG pays a 3.31% dividend while PubMatic Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and PubMatic Inc for 40 Days on average.
| NVS | PUBM | |
|---|---|---|
Market Cap | $268.57B | $850.88M |
Volume | 1,532,573 | 997,698 |
Sector | Health | Technology |
52-Week High | $168.62 | $19.18 |
52-Week Low | $121.80 | $6.28 |
Typical Hold Time | 82 Days | 40 Days |
Enterprise Value | $309.89B | $754.01M |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
PubMatic (PUBM) trades at $19.02, up 2.42% with a bullish technical signal and strong analyst consensus. The company shows mixed fundamentals with negative net income margins but positive cash flow and recent earnings beats. Recent Q2 2026 results exceeded expectations with 11% revenue growth, driven by mobile app and CTV segments. Technical indicators show bullish moving averages with neutral oscillators, while support sits at $18 and resistance at $19.
The outlook remains cautiously optimistic with 64.7% analyst buy ratings and a $19.89 price target. Key opportunities include AI-driven ad growth and market share gains, while risks involve persistent profitability challenges and competitive pressures in digital advertising. The CFO's planned retirement adds transitional uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
